{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:56:37Z","timestamp":1782435397733,"version":"3.54.5"},"reference-count":49,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2022.7074","type":"journal-article","created":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T15:31:09Z","timestamp":1650036669000},"page":"e227074","source":"Crossref","is-referenced-by-count":9,"title":["Association of Treatment With Antipsychotics, Antidepressants, or Both With Movement Disorders and Seizures Among Children and Adolescents With Depression in Korea"],"prefix":"10.1001","volume":"5","author":[{"given":"Soo Min","family":"Jeon","sequence":"first","affiliation":[{"name":"BK21 FOUR Community-Based Intelligent Novel Drug Discovery Education Unit, College of Pharmacy and Research Institute of Pharmaceutical Sciences, Kyungpook National University, Daegu, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hae-Young","family":"Park","sequence":"additional","affiliation":[{"name":"BK21 FOUR Community-Based Intelligent Novel Drug Discovery Education Unit, College of Pharmacy and Research Institute of Pharmaceutical Sciences, Kyungpook National University, Daegu, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Park","sequence":"additional","affiliation":[{"name":"Red Cross College of Nursing, Chung-Ang University, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Un Sun","family":"Chung","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, School of Medicine, Kyungpook National University, and Department of Psychiatry, Kyungpook National University Children's Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Won","family":"Kwon","sequence":"additional","affiliation":[{"name":"BK21 FOUR Community-Based Intelligent Novel Drug Discovery Education Unit, College of Pharmacy and Research Institute of Pharmaceutical Sciences, Kyungpook National University, Daegu, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2022,4,15]]},"reference":[{"issue":"4","key":"zoi220225r1","first-page":"1","article-title":"Practice guideline for the treatment of patients with major depressive disorder (revision).","volume":"157","author":"American Psychiatric Association","year":"2000","journal-title":"Am J Psychiatry"},{"issue":"2","key":"zoi220225r2","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/1529-1006.00008","article-title":"Treatment and prevention of depression.","volume":"3","author":"Hollon","year":"2002","journal-title":"Psychol Sci Public Interest"},{"issue":"3","key":"zoi220225r3","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1192\/bjp.178.3.234","article-title":"Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors.","volume":"178","author":"Thase","year":"2001","journal-title":"Br J Psychiatry"},{"issue":"2","key":"zoi220225r4","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S0193-953X(02)00107-7","article-title":"Background and rationale for the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study.","volume":"26","author":"Fava","year":"2003","journal-title":"Psychiatr Clin North Am"},{"issue":"6","key":"zoi220225r5","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1080\/15622975.2019.1635270","article-title":"Results of the European Group for the Study of Resistant Depression (GSRD)\u2014basis for further research and clinical practice.","volume":"20","author":"Bartova","year":"2019","journal-title":"World J Biol Psychiatry"},{"key":"zoi220225r6","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.psychres.2017.03.006","article-title":"Epidemiology of pharmaceutically treated depression and treatment resistant depression in Taiwan.","volume":"252","author":"Fife","year":"2017","journal-title":"Psychiatry Res"},{"issue":"3","key":"zoi220225r7","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1080\/13651501.2017.1306082","article-title":"Pharmacological treatment of unipolar depressive disorders: summary of WFSBP guidelines.","volume":"21","author":"Bauer","year":"2017","journal-title":"Int J Psychiatry Clin Pract"},{"issue":"S2","key":"zoi220225r8","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/bdi.12701","article-title":"Treating depression with adjunctive antipsychotics.","volume":"20","author":"Mulder","year":"2018","journal-title":"Bipolar Disord"},{"issue":"3","key":"zoi220225r9","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/phar.1204","article-title":"Augmentation with atypical antipsychotics for depression: a review of evidence-based support from the medical literature.","volume":"33","author":"Wright","year":"2013","journal-title":"Pharmacotherapy"},{"issue":"9","key":"zoi220225r10","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1176\/appi.ajp.2009.09030312","article-title":"Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials.","volume":"166","author":"Nelson","year":"2009","journal-title":"Am J Psychiatry"},{"issue":"1","key":"zoi220225r11","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jtcvs.2006.03.035","article-title":"Randomized controlled trials do not reflect reality: real-world analyses are critical for treatment guidelines!","volume":"132","author":"Grapow","year":"2006","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"2","key":"zoi220225r12","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-024537","article-title":"Analysis and reporting of adverse events in randomised controlled trials: a review.","volume":"9","author":"Phillips","year":"2019","journal-title":"BMJ Open"},{"issue":"9","key":"zoi220225r14","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1001\/jamapsychiatry.2015.0500","article-title":"Treatment of young people with antipsychotic medications in the United States.","volume":"72","author":"Olfson","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"23","key":"zoi220225r15","doi-asserted-by":"publisher","first-page":"e3784","DOI":"10.1097\/MD.0000000000003784","article-title":"National trends in off-label use of atypical antipsychotics in children and adolescents in the United States.","volume":"95","author":"Sohn","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"zoi220225r16","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1089\/cap.2017.0111","article-title":"Nationwide epidemiologic study of atypical antipsychotic use among pediatric population with mental illness in Korea.","volume":"28","author":"Lee","year":"2018","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"12","key":"zoi220225r17","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1007\/s00787-020-01488-6","article-title":"Prescribing antipsychotics in child and adolescent psychiatry: guideline adherence.","volume":"29","author":"Dinnissen","year":"2020","journal-title":"Eur Child Adolesc Psychiatry"},{"issue":"3","key":"zoi220225r18","article-title":"Review of the safety of second-generation antipsychotics: are they really \u201catypically\u201d safe for youth and adults?","volume":"14","author":"Briles","year":"2012","journal-title":"Prim Care Companion CNS Disord"},{"issue":"2","key":"zoi220225r19","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s00787-006-0580-1","article-title":"Management of psychiatric disorders in children and adolescents with atypical antipsychotics: a systematic review of published clinical trials.","volume":"16","author":"Jensen","year":"2007","journal-title":"Eur Child Adolesc Psychiatry"},{"issue":"1","key":"zoi220225r20","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/sj.npp.1300327","article-title":"A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial.","volume":"29","author":"Sikich","year":"2004","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"zoi220225r21","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s00787-020-01525-4","article-title":"Risk of seizures associated with antipsychotic treatment in pediatrics with psychiatric disorders: a nested case-control study in Korea.","volume":"30","author":"Jeon","year":"2021","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"zoi220225r22","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.668704","article-title":"Association between antipsychotic treatment and neurological adverse events in pediatric patients: a population-based cohort study in Korea.","volume":"12","author":"Jeon","year":"2021","journal-title":"Front Psychiatry"},{"issue":"4","key":"zoi220225r23","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"61","author":"von Elm","year":"2008","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"zoi220225r25","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1001\/jamapsychiatry.2018.3421","article-title":"Association of antipsychotic treatment with risk of unexpected death among children and youths.","volume":"76","author":"Ray","year":"2019","journal-title":"JAMA Psychiatry"},{"issue":"2","key":"zoi220225r26","doi-asserted-by":"publisher","first-page":"179","DOI":"10.2165\/11585350-000000000-00000","article-title":"Management of schizophrenia in children and adolescents: focus on pharmacotherapy.","volume":"71","author":"Masi","year":"2011","journal-title":"Drugs"},{"issue":"4","key":"zoi220225r27","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.cpem.2012.09.005","article-title":"Adverse effects and toxicity of the atypical antipsychotics: what is important for the pediatric emergency medicine practitioner.","volume":"13","author":"Rasimas","year":"2012","journal-title":"Clin Pediatr Emerg Med"},{"issue":"3","key":"zoi220225r28","first-page":"148","article-title":"Extrapyramidal symptoms associated with antidepressants\u2014a review of the literature and an analysis of spontaneous reports.","volume":"22","author":"Madhusoodanan","year":"2010","journal-title":"Ann Clin Psychiatry"},{"issue":"2","key":"zoi220225r29","doi-asserted-by":"publisher","first-page":"91","DOI":"10.2165\/00002018-200225020-00004","article-title":"Effects of psychotropic drugs on seizure threshold.","volume":"25","author":"Pisani","year":"2002","journal-title":"Drug Saf"},{"issue":"1","key":"zoi220225r30","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1186\/s12888-014-0340-6","article-title":"Systematic review of management for treatment-resistant depression in adolescents.","volume":"14","author":"Zhou","year":"2014","journal-title":"BMC Psychiatry"},{"issue":"9","key":"zoi220225r31","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1046\/j.1528-1157.2002.49901.x","article-title":"The neurodevelopmental impact of childhood-onset temporal lobe epilepsy on brain structure and function.","volume":"43","author":"Hermann","year":"2002","journal-title":"Epilepsia"},{"key":"zoi220225r32","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.jcrc.2016.07.017","article-title":"Immortal time bias in observational studies of time-to-event outcomes.","volume":"36","author":"Jones","year":"2016","journal-title":"J Crit Care"},{"issue":"4","key":"zoi220225r33","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1093\/aje\/kwm324","article-title":"Immortal time bias in pharmaco-epidemiology.","volume":"167","author":"Suissa","year":"2008","journal-title":"Am J Epidemiol"},{"issue":"11","key":"zoi220225r34","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.1097\/CCM.0b013e3181b7fbbb","article-title":"Immortal time bias in critical care research: application of time-varying Cox regression for observational cohort studies.","volume":"37","author":"Shintani","year":"2009","journal-title":"Crit Care Med"},{"issue":"2","key":"zoi220225r35","doi-asserted-by":"publisher","first-page":"240","DOI":"10.4088\/JCP.08m04212","article-title":"Polypharmacy in children and adolescents treated for major depressive disorder: a claims database study.","volume":"70","author":"McIntyre","year":"2009","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"zoi220225r36","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.16m10971","article-title":"Antipsychotic medication treatment patterns in adult depression.","volume":"79","author":"Gerhard","year":"2018","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"zoi220225r37","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1080\/03007995.2017.1294055","article-title":"The use of adjunctive antipsychotics to treat depression in UK primary care.","volume":"33","author":"Lamy","year":"2017","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"zoi220225r38","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1177\/0706743716664885","article-title":"Systematic review of clinical practice guidelines for failed antidepressant treatment response in major depressive disorder, dysthymia, and subthreshold depression in adults.","volume":"62","author":"MacQueen","year":"2017","journal-title":"Can J Psychiatry"},{"issue":"1","key":"zoi220225r39","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/JCP.0000000000001322","article-title":"Guideline adherence of monitoring antipsychotic use for nonpsychotic indications in children and adolescents: a patient record review.","volume":"41","author":"Dinnissen","year":"2021","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"zoi220225r40","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1517\/17425255.2014.885504","article-title":"Clinically relevant interactions between newer antidepressants and second-generation antipsychotics.","volume":"10","author":"Spina","year":"2014","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"2","key":"zoi220225r41","first-page":"99","article-title":"Interactions between the cytochrome P450 system and the second-generation antipsychotics.","volume":"28","author":"Prior","year":"2003","journal-title":"J Psychiatry Neurosci"},{"issue":"1","key":"zoi220225r42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/tpj.2010.73","article-title":"Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses.","volume":"11","author":"Fleeman","year":"2011","journal-title":"Pharmacogenomics J"},{"issue":"16","key":"zoi220225r43","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1001\/archinte.165.16.1882","article-title":"Atypical antipsychotics and parkinsonism.","volume":"165","author":"Rochon","year":"2005","journal-title":"Arch Intern Med"},{"issue":"9657","key":"zoi220225r44","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis.","volume":"373","author":"Leucht","year":"2009","journal-title":"Lancet"},{"key":"zoi220225r45","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/656370","article-title":"Second-generation antipsychotics and extrapyramidal adverse effects.","volume":"2014","author":"Divac","year":"2014","journal-title":"Biomed Res Int"},{"issue":"1","key":"zoi220225r46","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/schbul\/sbq042","article-title":"Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons.","volume":"38","author":"Rummel-Kluge","year":"2012","journal-title":"Schizophr Bull"},{"issue":"7","key":"zoi220225r47","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1358\/dot.2003.39.7.799445","article-title":"Antipsychotic medication and seizures: a review.","volume":"39","author":"Hedges","year":"2003","journal-title":"Drugs Today (Barc)"},{"issue":"2","key":"zoi220225r48","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.seizure.2012.10.009","article-title":"Antipsychotics and seizures: higher risk with atypicals?","volume":"22","author":"Lertxundi","year":"2013","journal-title":"Seizure"},{"issue":"5","key":"zoi220225r49","doi-asserted-by":"publisher","first-page":"e573","DOI":"10.4088\/JCP.15m09898","article-title":"Comparative risk of seizure with use of first- and second-generation antipsychotics in patients with schizophrenia and mood disorders.","volume":"77","author":"Wu","year":"2016","journal-title":"J Clin Psychiatry"},{"key":"zoi220225r13","volume-title":"The Illusion of Evidence-Based Medicine: Exposing the Crisis of Credibility in Clinical Research","author":"McHenry","year":"2020"},{"key":"zoi220225r24","volume-title":"Guidelines for ATC Classification and DDD Assignment 2019","author":"WHO Collaborating Centre for Drug Statistics Methodology","year":"2018"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2791163\/jeon_2022_oi_220225_1649432828.11266.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T15:31:25Z","timestamp":1650036685000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2791163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,15]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.7074","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,15]]}}}